Receptor News and Research

RSS

Cancers use body's own defences to resist drugs

CANCER RESEARCH UK scientists have discovered that tumours are able to recruit part of the body's defence system to protect them from the effect of a drug designed to block the supply of blood to the tumour.

4 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

New insight into itch and pain

A new study of itch adds to growing evidence that the chemical signals that make us want to scratch are the same signals that make us wince in pain.

3 May 2011

Hebei Aoxing Pharma receives Chinese patent for naloxone sublingual film

Aoxing Pharmaceutical, a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for naloxone sublingual film.

3 May 2011

Animal studies reveal new route to treating heart disease

Scientists at Johns Hopkins have shown in laboratory experiments in mice that blocking the action of a signaling protein deep inside the heart’s muscle cells blunts the most serious ill effects of high blood pressure on the heart. These include heart muscle enlargement, scar tissue formation and loss of blood vessel growth.

2 May 2011

ARVO announces 2011 award recipients in retinal research

The Association for Research in Vision and Ophthalmology is pleased to announce its 2011 ARVO Award recipients. These award recipients will be acknowledged at the ARVO 2011 Annual Meeting, May 1 - 5, in Fort Lauderdale, Fla.

2 May 2011

Senomyx first-quarter 2011 revenues rise up 13%

Senomyx, Inc., a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries, today provided a corporate update and reported financial results for the first quarter ended March 31, 2011.

30 Apr 2011

Scientists discover how immune cells recognize invading pathogens in the body

Scientists at Cedars-Sinai Medical Center have discovered how a molecular receptor on the surface of white blood cells identifies when invading fungi have established direct contact with the cell surface and pose an infectious threat.

30 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

Blood levels of inflammation-controlling protein linked to childrens' risk of developing diabetes

Decreasing blood levels of a protein that helps control inflammation may be a red flag that could help children avoid type 1 diabetes, researchers say.

28 Apr 2011

Study finds increase in implementation of evidence-based therapies for myocardial infarction

In an analysis of data from a coronary care registry in Sweden, between 1996-2007 there was an increase in the prevalence of use of evidence-based invasive procedures and pharmacological therapies for treatment of a certain type of heart attack, and a decrease in the rate of death at 30 days and one year after a heart attack for these patients, according to a study in the April 27 issue of JAMA.

28 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Scientists weaken long-term memory

Could veterans of war, rape victims and other people who have seen horrific crimes someday have the traumatic memories that haunt them weakened in their brains? In a new study, UCLA life scientists report a discovery that may make the reduction of such memories a reality.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Promising pain medication may decrease ability to fight off sepsis

Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.

27 Apr 2011

Clinical study: Plant extract can fight effectively against hay fever

Fighting hay fever with a plant extract - this works, as was shown in a clinical study conducted by researchers of the Center of Allergy & Environment of Helmholtz Zentrum München and Technische Universität München.

27 Apr 2011

Biologists determine molecular structure of GluN2D receptor subunit

Structural biologists at Cold Spring Harbor Laboratory in collaboration with colleagues at Emory University have determined the molecular structure of a key portion, or subunit, of a receptor type commonly expressed in brain cells.

27 Apr 2011

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Cancer researchers at hundreds of sites nationwide are about to launch a SWOG-led clinical trial that could keep thousands of breast cancer patients from getting chemotherapy that is unlikely to do them any good.

27 Apr 2011

Brain-derived protein in colorectal cancer

Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored.

27 Apr 2011